Date: 2011-03-30

Type of information: Collaboration agreement


Company: MedImmune (USA) Inserm Transfert (France) Inserm (France)

Therapeutic area: Cancer - Oncology - Respiratory diseases - Inflammatory diseases - Autoimmune diseases

Type agreement:


Action mechanism:



MedImmune, the global biologics business of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm) have announced a three-year strategic collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. Research will explore translational biology and new disease mechanisms, as well as evaluate potential drug candidates.
The collaboration calls for MedImmune funding and joint scientific collaboration commencing with 10 research projects, maximizing Inserm’s unique capability to conduct research by blended physician/biologist teams, and their unparalleled link to patient populations and understanding of human diseases. Additional research projects are being evaluated.

Financial terms:

Via decision-making governance by a Joint Steering Committee (JSC), MedImmune will fund projects to be executed with Inserm for both pre-clinical and clinical research, and will execute other activities to help identify promising approaches to advance drug candidates for patients with unmet medical needs.

Latest news:

Is general: Yes